Now showing items 1-1 of 1
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [Article]
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the ...